Research Corporation Technologies

What Research Corporation Technologies does

Research Corporation Technologies (RCT), founded in 1987 in Tucson, Arizona, is a privately held technology investment and management company that operates three integrated businesses across the life-sciences value chain. Its licensing program manages a portfolio of patented life-science technologies — including the Pichia GlycoSwitch and ClearColi protein expression systems, the ABDURINS CH2-domain antibody scaffold, and origin of approved therapeutics such as VIMPAT (lacosamide, licensed to UCB) and the Shingrix shingles vaccine antigen (licensed to GSK in 2000, FDA-approved 2017). The RCT Ventures program invests seed and early-stage capital into biomedical and medical device companies, sourced in part through the MedTech Innovator accelerator (2026 cohort of 65 startups selected from 1,835 applicants). Finally, RCT owns and operates CDMO/CRO subsidiaries: Codis (commercial spray drying and amorphous solid dispersion manufacturing at more than 400,000 sq ft of cGMP capacity across the US and UK), AustinPx (fee-for-service formulation and KinetiSol-based bioavailability enhancement, formerly DisperSol Technologies), and Translational Drug Development (TD2, an oncology development organization acquired in 2020).

The company's business model is multi-channel. Licensing royalties and milestones are earned from nonexclusive and exclusive deals on its technology platform portfolio; this includes composition-of-matter royalties on FDA-approved products. Venture returns are generated through equity holdings in portfolio companies such as seqWell, Jenrin Discovery, Esperance Pharmaceuticals, BioGrammatics, and Option 3. Operating-subsidiary revenues come from Codis's CDMO services, AustinPx's formulation development, and TD2's preclinical and clinical oncology services. RCT holds more than $500 million in assets to underwrite long-dated biomedical bets, and its customers span major pharmaceutical companies (UCB, GSK), biotech firms (ThromboGenics, Lucigen, BioGrammatics), and a portfolio of early-stage ventures.

RCT's competitive posture rests on its origin and licensing position on validated, court-enforceable IP (e.g., Vimpat patent RE38,551 confirmed valid in the Delaware District Court in 2016), a global manufacturing footprint (Tucson HQ; St. Louis, Seymour IN, Haverhill UK, and Scottsdale AZ sites; Belgium-served markets), and a self-reinforcing deal origination engine through MedTech Innovator. Public disclosure of pricing and contract terms is limited — licensing is negotiated case-by-case — and revenue, ownership structure, and detailed financials are not publicly disclosed.

Name

Research Corporation Technologies

Legal name

Research Corporation Technologies

Website

https://rctech.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Research Corporation Technologies is a privately held Tucson, Arizona–based technology investment and management company that licenses patented biomedical technologies, invests seed and early-stage capital in life-sciences ventures via RCT Ventures, and operates CDMO/CRO subsidiaries (Codis, AustinPx, TD2) serving pharmaceutical and biotechnology customers.

Ownership category

akta.pro rank

Product category

Biomedical Technology Investment and Licensing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Patent Owners & Lessors (6794), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Biomedical technology licensing
• Life science venture capital
• Protein expression platforms
• Pharmaceutical CDMO services
• Biologics patent licensing

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure, Others

Revenue model

1. Technology Licensing: RCT licenses biomedical technologies to pharmaceutical and biotech companies through nonexclusive licensing programs, generating fees, milestones and royalties
2. Venture Capital Investments: RCT provides venture capital to early-stage biomedical companies through RCT Ventures program, generating returns through equity investments in portfolio companies
3. Asset Management: RCT manages technology assets with more than $500 million in assets to advance technology and product development through flexible, long-term investment options

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Research Corporation Technologies invests in, develops, and licenses biomedical and life-science technologies originating from universities and research institutions, providing early-stage funding, patent prosecution, and commercialization pathways to pharmaceutical and biotechnology companies. RCT complements its licensing and venture activity with operating subsidiaries that deliver contract development, manufacturing (CDMO), and oncology drug development services, while running the MedTech Innovator accelerator to identify and scale early-stage medical device opportunities.

Product overview

Research Corporation Technologies is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT operates two main offerings: (1) venture investments through RCT Ventures, which funds early-stage companies including Codis (CDMO for spray drying and ASDs), AustinPx (formulation development using KinetiSol technology), Translational Drug Development (TD2, oncology CRO), and various portfolio companies like Jenrin Discovery and Esperance Pharmaceuticals; and (2) a technology licensing portfolio featuring protein expression platforms (Pichia GlycoSwitch, ClearColi), the ABDURINS scaffold for biologics discovery, and licensed technologies like the Shingrix vaccine antigen and VIMPAT epilepsy drug. RCT also operates MedTech Innovator, a venture competition and accelerator for early-stage medical device companies.

Differentiator

Problem solved

Functional benefit

Brands

• MedTech Innovator: A venture competition and virtual accelerator designed to identify and support innovative early-stage medical device companies
• ABDURINS
• Codis
• AustinPx

Products and services

• Pichia GlycoSwitch Protein Expression System Yeast-based recombinant protein expression platform in Pichia pastoris that modifies glycosylation of recombinant proteins to generate human-like glycoproteins, used by pharmaceutical and biotechnology companies for therapeutic protein production.
• Endotoxin-free ClearColi Expression System The first E. coli-based recombinant expression system that lacks unwanted endotoxin, enabling production of proteins virtually free of endotoxin contamination for faster and more accurate screening of biological targets in drug discovery research.
• ABDURINS (CH2 Domain Scaffold) Engineered antigen-binding protein scaffold based on CH2 domains that retain the long half-life of an antibody's CH2 region while offering small size, enhanced stability, and tunable epitope binding for therapeutic development.
• VIMPAT (lacosamide) Anti-epileptic drug approved as adjunctive therapy and monotherapy for treatment of partial-onset seizures in adults with epilepsy; developed and patented by RCT and licensed to UCB for global commercialization.
• Shingles Vaccine Antigen (Shingrix) Truncated form of glycoprotein E (gE protein) from the Varicella Zoster Virus used as the antigen in GSK's Shingrix shingles prevention vaccine; exclusively licensed to GlaxoSmithKline in 2000.
• MedTech Innovator Venture competition and virtual accelerator that identifies, mentors, and funds innovative early-stage medical device companies through a cohort program culminating in competitions for a share of prize funding at major industry conferences.
• Codis Global contract development and manufacturing organization (CDMO) specializing in commercial spray drying, amorphous solid dispersions (ASDs), particle engineering, and finished dose manufacturing for pharmaceutical, consumer health, nutraceutical, and OTC customers across more than 400,000 sq ft of cGMP facilities in St. Louis, Seymour, and Haverhill UK.
• AustinPx Fee-for-service contract development and manufacturing organization (CDMO) offering preclinical through Phase II formulation and process development and GMP manufacturing of oral dosage forms, with specialization in bioavailability enhancement using KinetiSol technology.
• Translational Drug Development (TD2) Oncology development organization providing rigorous and high-throughput translational preclinical development combined with regulatory affairs expertise to customize clinical trial design and execution for oncology-focused pharmaceutical and biotechnology companies.
• RCT Ventures Venture capital program that invests equity in start-up and early-stage companies with technologies that have the potential to become significant biomedical products with a definite competitive edge.
• Jenrin Discovery RCT Ventures portfolio company developing safer and more effective orally administered small molecule therapeutics for chronic diseases including obesity, diabetes, and autoimmune and inflammatory disorders.
• Esperance Pharmaceuticals RCT Ventures portfolio company developing a new class of targeted anticancer drugs using its Cationic Lytic Peptide (CLYP) platform technology, with lead candidate EP-100 targeting the LHRH-Receptor on ovarian, endometrial, and breast cancer cells.
• Option 3 Medical device development and commercialization vehicle formed by RCT and James Dreher to invest in select medical device products, including the Weck EFx Endo Fascial Closure System developed by Axiom Technology Partners.

Quantifiable outcome

• Shingrix demonstrated over 90% efficacy across all age groups in prevention of shingles
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Ten partnerships are on record, tiered core and major.

• GEAcoreTechnology or Integration · 4 March 2026Codis purchased GEA Pharma-SD type PSD-4 solvent-capable spray dryer for commercial manufacturing expansion at Haverhill, UK facility.
• Univar SolutionsmajorChannel Partner/ Reseller/ Distributor · 15 March 2022Distribution agreement where Univar Solutions offers Particle Dynamics' compressible calcium and magnesium carbonates and microencapsulated vitamins and minerals to customers across the United States and Canada.
• Deep LensmajorStrategic or Co-development Partner · 16 September 2021Strategic partnership between TD2 and Deep Lens to enhance access to tailored oncology treatments and novel clinical studies through Deep Lens' proprietary clinical trial matching solution VIPER.
• VTU TechnologycoreTechnology or Integration · 3 December 2014Partnership to offer custom glycoprotein production in Pichia GlycoSwitch expression system.
• BioGrammaticscoreTechnology or Integration · 4 June 2013Partnership to commercialize and distribute Pichia GlycoSwitch Expression System for modifying glycosylation of recombinant proteins. BioGrammatics provides expression system kits and services; RCT oversees commercial licensing programs.
• Lucigen CorporationcoreTechnology or Integration · 1 May 2013Partnership to commercialize and distribute CleanColi Expression System, the first E. coli-based recombinant system lacking unwanted endotoxin. Lucigen produces and sells kits containing CleanColi competent cells; RCT is responsible for commercial licensing programs.
• Antitope Ltd.coreStrategic or Co-development Partner · 22 April 2013Research agreement to re-engineer a toxic protein warhead for next generation antibody-drug-conjugates (ADCs) using Antitope's proprietary Composite Protein technology. Resulting deimmunized protein expected to have therapeutic applications in cancer treatment.
• IsogenicacoreTechnology or Integration · 11 July 2012Partnership to access Isogenica's CIS display platform for screening proprietary libraries of CH2 domain antigen-binding protein scaffolds (ABDURINS). CIS display can screen significantly larger libraries and isolate and optimize lead binders faster than phage display.
• National Cancer Institute (NIH)coreStrategic or Co-development PartnerCooperative Research and Development Agreement (CRADA) with NIH's Protein Interactions Group for development of CH2 domain-based biologics discovery platform (ABDURINS).
• IRBMcoreStrategic or Co-development PartnerPartnership allowing partners and licensees access to broad ABDURINS product discovery and development program through early nonclinical testing.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Royalty Pharma: Royalty Pharma is the largest dedicated acquirer of biopharmaceutical royalties and milestone rights, including on assets like VIMPAT-class drugs. It represents a comparable capital provider and exit option for RCT's licensing economics.
• Lonza Group: Lonza is one of the world's largest CDMOs across biologics, small molecules, and cell therapies. It is comparable in operating scale to Codis/AustinPx's contract manufacturing business lines within RCT.
• Catalent: Catalent is a global CDMO offering formulation, spray drying, and drug product manufacturing. Codis operates as a comparable but more specialized spray-drying/ASD-focused CDMO within RCT's portfolio.
• WuXi STA: WuXi STA is a global CDMO providing development, manufacturing, and spray drying services at scale. It is a direct comparator in formulation and drug product manufacturing services offered through RCT's Codis and AustinPx subsidiaries.

Direct peers

• Halozyme Therapeutics: Halozyme licenses its ENHANZE drug delivery platform to major pharma companies for royalty income, exemplifying the proprietary-platform licensing-and-royalty business model that RCT pursues with ABDURINS, Pichia, and ClearColi.
• Hercules Capital: Hercules is a specialty finance company providing venture debt and growth capital to life science and technology companies, comparable to RCT's venture capital programs supporting early-stage biomedical companies.
• Abingworth: Abingworth is a life sciences-focused investment firm that provides funding and development support to biotech companies through venture and royalty-based financing, closely mirroring RCT's venture + licensing model.
• BioGeneration Ventures (BGV): BGV is an early-stage life sciences venture capital firm based in Europe, comparable to RCT Ventures in funding and developing early-stage biotech and biomedical platform companies.

Emerging players

• Pfenex (now part of Ligand): Pfenex developed the Pichia pastoris-based protein expression platform (similar to RCT's Pichia GlycoSwitch) before acquisition by Ligand. It provides a focused comparison for RCT's yeast-based recombinant expression technology portfolio.

Others

• BroadOak Capital Partners: BroadOak is a life sciences-focused financial investor that co-led the acquisition of Particle Dynamics (now Codis) with RCT. It functions as a repeat co-investor and adjacent financial partner in RCT's deal flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments29 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Research Corporation Technologies